Cybin Transitions to Nasdaq with New "HELP" Ticker as Helus Pharma, Advancing Phase 3 Depression Treatment
核心洞察
Cybin (搜索) Inc. will transfer its U.S. stock listing from NYSE American (搜索) to Nasdaq (搜索) Global Market on January 5, 2026, adopting the new ticker symbol "HELP" and rebranding as Helus Pharma (搜索).
The clinical-stage pharmaceutical company is developing CYB003 in Phase 3 studies for major depressive disorder (搜索), which has received FDA Breakthrough Therapy Designation.
Cybin (搜索) also has CYB004 in Phase 2 trials for generalized anxiety disorder (搜索) and maintains an extensive pipeline of investigational psychedelic compounds for mental health conditions.
Cybin (搜索) Inc., a clinical-stage pharmaceutical company developing next-generation psychedelic treatments for mental health conditions, announced it will voluntarily transfer its U.S. stock exchange listing from the NYSE American (搜索) to the Nasdaq (搜索) Global Market effective January 5, 2026. The company will simultaneously rebrand as Helus Pharma (搜索) and adopt the new ticker symbol "HELP" across both U.S. and Canadian exchanges.
The transition represents a strategic milestone for the Toronto-based company as it advances its lead candidate CYB003 through Phase 3 clinical trials for the adjunctive treatment of major depressive disorder (搜索). The compound has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (搜索), highlighting its potential to address significant unmet medical needs in mental healthcare.
Advanced Clinical Pipeline Targeting Mental Health Disorders
Cybin (搜索)'s clinical portfolio centers on two key investigational compounds addressing major mental health conditions. CYB003, the company's most advanced asset, is currently in Phase 3 studies for major depressive disorder (搜索) as an adjunctive treatment. The FDA's Breakthrough Therapy Designation for CYB003 indicates the agency's recognition of the compound's potential to provide substantial improvement over existing treatments for patients with serious conditions.
The company is also developing CYB004, which is in Phase 2 studies for generalized anxiety disorder (搜索). Beyond these lead programs, Cybin (搜索) maintains an extensive research pipeline of investigational psychedelic compounds designed to provide effective and durable results for patients suffering from mental health conditions.
Strategic Corporate Evolution
"We are pleased to join the community of global pharmaceutical companies listed on Nasdaq (搜索) and thank the NYSE American (搜索) for supporting the company over the last four years since our initial listing," said Eric So, interim chief executive officer of Cybin (搜索). "The transfer to Nasdaq marks the next step in the evolution of Cybin into a global pharmaceutical company."
The company expects its common shares will cease trading on the NYSE American (搜索) at market close on January 4, 2026, and commence trading on Nasdaq (搜索) at market open on January 5, 2026. The new "HELP" ticker symbol will be implemented simultaneously across both the Nasdaq Global Market and Cboe Canada exchanges.
Addressing Mental Health Treatment Gaps
Founded in 2019, Cybin (搜索) operates across multiple jurisdictions including Canada, the United States, the United Kingdom, and Ireland. The company positions itself as addressing a large unmet need for people who suffer from mental health conditions through the development of novel psychedelic-based therapies.
The company's approach focuses on engineering proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches for mental health treatment regimens. This comprehensive strategy aims to change the mental health treatment landscape through the introduction of drugs that provide both effective and durable therapeutic outcomes.
Cybin (搜索)'s transition to Nasdaq (搜索) and rebranding as Helus Pharma (搜索) reflects the company's maturation from a research-stage entity to a clinical-stage pharmaceutical company with advanced assets in late-stage development. The move aligns with the company's goal of establishing itself within the broader pharmaceutical industry as it progresses toward potential regulatory approvals and commercialization of its psychedelic-based mental health treatments.